<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disease risks and management implications of selected &lt;em&gt;SERPINA1&lt;/em&gt; genotypes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disease risks and management implications of selected <em>SERPINA1</em> genotypes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Disease risks and management implications of selected <em>SERPINA1</em> genotypes</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup span="2" width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Genotype</td> <td class="subtitle1">AAT level<sup>¶</sup></td> <td class="subtitle1">Lung disease</td> <td class="subtitle1">Liver disease</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Unaffected (no variant or mild deficiency variants only)</td> </tr> <tr> <td class="indent1">PI*MM</td> <td><span class="nowrap_whitespace">20-53 micromol/L<br/> 100-220 mg/dL</span></td> <td> <ul> <li>Not at increased risk of lung disease</li> </ul> </td> <td> <ul> <li>Not at increased risk of liver disease</li> </ul> </td> </tr> <tr> <td class="indent1">PI*SS</td> <td><span class="nowrap_whitespace">15-33 micromol/L<br/> 100-200 mg/dL</span></td> <td> <ul> <li>Not considered at increased risk of lung disease</li> </ul> </td> <td> <ul> <li>Not considered at increased risk for liver disease</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Heterozygous for <em>SERPINA1</em> disease variants</td> </tr> <tr> <td class="indent1"> PI*MZ <p class="extra_spacing">-or-</p> PI*SZ</td> <td>17-33 micromol/L<br/> 90-210 mg/dL <p class="extra_spacing">-or-</p> 8-16 micromol/L<br/> 75-120 mg/dL</td> <td> <ul> <li>Emphysema risk is thought to be confined to smokers (longitudinal data are lacking)</li> <li>Never-smokers with normal lung function generally do not require serial monitoring of lung function</li> <li>Not considered candidates for augmentation therapy</li> </ul> </td> <td> <ul> <li>Higher than average risk for liver disease</li> <li>Liver disease often exacerbated by concomitant steatohepatitis</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Homozygous or compound heterozygous for <em>SERPINA1</em> disease variants</td> </tr> <tr> <td class="indent1">PI*ZZ</td> <td><span class="nowrap_whitespace">2.5-7 micromol/L<br/> 20-45 mg/dL</span></td> <td> <ul> <li>Emphysema risk: <ul> <li>Increased in never-smokers</li> <li>Markedly increased in smokers</li> <li>Likely increased following exposure to occupational dusts, marijuana, vaping</li> </ul> </li> <li>Follow pulmonary function tests every 6 to 12 months</li> <li>Candidates for augmentation therapy if emphysema is established</li> <li>Lung transplantation may be an option</li> </ul> </td> <td> <ul> <li>Lifetime prevalence of cirrhosis in PI*ZZ homozygotes up to 40%</li> <li>Cirrhosis risk may appear higher in never-smokers, as they may escape mortality risk of emphysema</li> <li>Follow liver biochemical tests every 6 to 12 months; consider elastography and ultrasound yearly</li> <li>Liver transplantation may be an option</li> </ul> </td> </tr> <tr> <td class="indent1">Null</td> <td><span class="nowrap_whitespace">0 micromol/L<br/> 0 mg/dL</span></td> <td> <ul> <li>High risk of developing emphysema</li> </ul> </td> <td> <ul> <li>Not increased (there is no abnormal protein to polymerize or accumulate in hepatocytes)</li> </ul> </td> </tr> <tr> <td class="indent1">PI*FF<sup>Δ</sup></td> <td><span class="nowrap_whitespace">20-53 micromol/L<br/> 100-220 mg/dL</span></td> <td> <ul> <li>Increased risk of emphysema, although data are lacking to estimate the magnitude of the risk</li> </ul> </td> <td> <ul> <li>Not increased (abnormal protein does not polymerize intrahepatically)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Homozygosity for Z, the most common AAT disease variant (PI*ZZ), accounts for &gt;95% of all clinical disease. Lung disease and liver disease may be exacerbated by other conditions such as smoking or steatohepatitis, respectively. In addition to emphysema and liver disease, PI*ZZ individuals are also predisposed to panniculitis and ANCA-positive vasculitis. Heterozygosity for Z (PI*MZ) has a prevalence of approximately 3% in the United States.</div><div class="graphic_footnotes"><p>AAT: alpha-1 antitrypsin; PI: protease inhibitor (another name for AAT); ANCA: antineutrophil cytoplasmic antibody; ELISA: enzyme-linked immunosorbent assay; AATD: alpha-1 antitrypsin deficiency.</p>
<p>¶ Molarity is generally determined by ELISA; concentration in mg/dL can be determined by nephelometry. The protective threshold for AAT is considered to be 11 micromol/L (57 mg/dL) or above.</p>
Δ The F allele (Arg223Cys) is very rare. It produces normal AAT protein levels, but the protein is dysfunctional with markedly impaired antineutrophil elastase activity. PI*FF individuals are at risk for emphysema; however, assaying their serum AAT level may be insufficient to diagnose AATD.</div><div id="graphicVersion">Graphic 129289 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
